Kelvin A. Baggett, MD, MPH, MBA
About Kelvin A. Baggett, MD, MPH, MBA
A nationally recognized, strategic, results-oriented leader with experience as a physician, clinical leader, operator, advisor, and investor. He brings a richly informed point of view on how to manage through complexity at scale and create value. That perspective was shaped through his positions in senior management and executive leadership in large complex organizations and privately held assets.
Currently, Kelvin serves as Managing Director, Head of Patient Impact and Chair of the EMPIRIC Institute. Most recently he served as Executive Vice President & Chief Impact Officer at McKesson, a Fortune 10 company. In that capacity, he had global responsibility for McKesson’s strategy and execution related to Sustainability & Environmental, Social and Governance (ESG) positions, practices and initiatives, Diversity, Equity and Inclusion, Corporate Impact, social impact, strategic partnerships, community relations and philanthropic giving through the McKesson Foundation.
Prior to joining McKesson, Kelvin served as Managing Director, Posterity Capital Group, a healthcare-dedicated investment firm targeting companies that enabled improvements in health and wellness. He also served as a Senior Advisor to Pharos Capital Group, a middle-market healthcare private equity firm.
Formerly, Kelvin was Chief Operating Officer for Health Care Navigator, a privately held, multi-state, asset management company focused on post-acute and long-term care. He was the SVP of Clinical Operations & Chief Clinical Officer for Tenet Healthcare Corporation, having initially joined Tenet as Chief Medical Officer. Before joining Tenet, Kelvin served as Chief Operating Officer, Clinical Services Group and VP of Clinical Strategies at HCA Healthcare.
During the COVID-19 pandemic in 2020, Kelvin served as a civic volunteer as the City of Dallas COVID-19 Health and Healthcare Access Czar. In support of that effort, he created the Dallas COVID-19 Alliance, a diverse group of business, governmental, educational, healthcare and civic leaders, to enhance collaboration in response to the pandemic. This alliance helped the city to navigate the pandemic while maintaining healthcare capacity and business activities.
Kelvin completed his medical training in Internal Medicine at the Yale University School of Medicine. He completed advance training as a Robert Wood Johnson Clinical Scholar at the Johns Hopkins University School of Medicine and as a Fellow at the Duke University School of Medicine. He earned his B.S. in Biology from the University of North Carolina at Chapel Hill, a Doctor of Medicine Degree from the East Carolina University School of Medicine, a Master of Public Health Degree from the Johns Hopkins Bloomberg School of Public Health, and a Master of Business Administration Degree from the Duke University Fuqua School of Business.
Currently, Kelvin sits on the board of DUMAC, the investment firm whose primary responsibility is the management of Duke University’s endowment assets. Current assets under management are approximately twenty-eight billion dollars. He was a prior member of the board of Dossia Consortium and has served on the investment and/or finance committees of several not-for-profit organizations.
View All Board Members here.
Managing Director, Head of Patient Impact and Chair